MMMwangana Mubita

Mwangana Mubita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mwangana Mubita has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors influencing anticoagulation control of patients on warfarin therapy at Windhoek Central Hospital’s Warfarin Clinic

    by Moses Mukwipure Thikukutu, Lauren Jenifer Jonkman, Bonifasius Siyuka Singu, Mwangana Mubita, Roger Karel Verbeeck

    Background: Thrombotic diseases are a global challenge. Warfarin remains the anticoagulant of choice in low- and middle-income countries. In 2017, a study reported suboptimal anticoagulation control of 29.4%, compared to the target of ≥ 65%, in patients who attended the Windhoek Central Hospital's warfarin clinic. Objective: Factors contributing to the suboptimal anticoagulation control had to be explored. Methods: To achieve this, 72 patients from the interventional cohort at the clinic were interviewed. Results: The majority (39%) of respondents had dosage-related factors, followed by 21% with diet-related factors, 19% reported factors associated with social determinants of health, and the least (5.6%) due to drug interactions in patients with a co-diagnosis of tuberculosis. Conclusion: The study highlighted the need for improved healthcare system support, such as equipping non-physician health cadres (pharmacists and nurses) with the ability to prescribe warfarin therapy and roll out point-of-care testing for patients with limited access to primary healthcare settings, improving access to medication at the primary healthcare facilities, and patient education to improve warfarin therapy outcomes.

  • Open Access

    Validation of the Coaguchek® XS INR point-of-care analyser to monitor the INR of patients at Windhoek Central Hospital, Namibia

    by Moses Thikukutu, Lauren Jonkman, Bonifasius Singu, Mwangana Mubita, Roger Verbeeck

    Background: The use of point-of-care INR (international normalised ratio) testing is on the rise because of its ability to facilitate quick clinical decisions as it allows for rapid turnaround time of INR results. Ensuring the quality of these tests is crucial when implementing them in new settings. Objective: This study aimed to assess the sensitivity, specificity, and clinical agreement between the CoaguChek® XS INR meter and the Beckman Coulter ACL 7000 automated coagulometer in outpatients undergoing warfarin therapy. Methods: A prospective cohort design was employed for this comparison. The analysis included Spearman’s correlation, a Bland-Altman plot, and a Cohen’s Kappa analysis of paired INR values. Key outcome measures included the percentage sensitivity, specificity, and clinical agreement of the two methods. A p-value < 0.05 was considered statistically significant. Results: The study involved 89 patients, predominantly female (59.4%), with a mean age of 46 years. Deep vein thrombosis was the most common indication for warfarin therapy (51.9%). The mean difference between INR values determined by the two methods was –0.15 (± 0.27, N = 89), and the Spearman rank correlation coefficient was 0.97 (p < 0.001, N = 89). A clinical agreement of 83.8% (p < 0.05) was obtained. The sensitivity was 94.4%, with specificities of 82.5% for subtherapeutic and 100% for supratherapeutic INRs. Conclusion: The CoaguChek® XS INR meter was proven to be a reliable alternative to the Beckman Coulter ACL 7000 automated coagulometer for monitoring INR results and adjusting warfarin therapy in well-trained patients with stable INR values. What this study adds: The CoaguChek® XS INR meter was proven to be a reliable alternative to the Beckman Coulter ACL 7000 automated coagulometer for monitoring INR results.

  • Migration to online pharmacy education in Namibia: Successes, challenges and competence implications

    by Dan Kibuule, Jennie Lates, Anthony Ishola, Ester Hango, Francis Kalemeera, Michael Knott, Daniel Mavu, Bonifasius Singu, Timothy Rennie, Irene Brinkmann, et al.

    Background: COVID-19, a global pandemic, has disrupted pharmacy education in Africa, due to unpreparedness to migrate to online Learning. Aim: To assess outcomes and challenges facing migration to online pharmacy education. Methods: An evaluation of implementation of online learning in the Bachelor of Pharmacy programme in Namibia using key informant feedback. The outcomes were outputs and challenges facing migration to online learning, and its impact on pass rates and scores. Results: The pooled mean score was higher in 2020 (66.2%), compared to 2019 (63.4%) and 2018 (62.1%), (p=0.076). A variety of platforms were used as alternatives or supplements to Moodle. The main challenges included inequalities in internet connectivity, monitoring and quality assurance, implementation of experiential learning, and reliability of online assessment. Conclusions: Whilst migration to online learning did not impact on pass rates, there is need for policies and systems to address programmatic challenges to eliminate inequalities in online pharmacy education.


  • Open Access

    Utility of medicines information leaflets in hypertensive care in a setting with low health literacy: A cross-sectional study

    by Mtungwazi Kudzinesta, Mwangana Mubita, Francis Kalemeera, Brian Godman, Ester Hango, Dan Kibuule

    Introduction: Higher levels of health literacy improve utilization of health information, medication adherence and outcomes. Few studies evaluate the utility of medicines information in hypertensive care in settings with low health literacy. Aim: To determine the level of health literacy and utility of medicines information leaflets (MILs) among hypertensive patients in public health care in Namibia. Methods: A hospital-based survey among hypertensive patients receiving care at a referral hospital in Namibia from the 8 June 2018 to 29 June 2018. Patient’s health literacy and utility of MIL were assessed using three literacy tools and a survey questionnaire. Quantitative data were analysed using descriptive statistics and qualitative thematic content analysis for factors associate with the utility of the MIL. Results: Of the 139 patients, 63% were female and the mean age was 45.7 (range: 19.0–84.0) years. Over 85.6% had of low literacy skills (Rapid Estimate of Literacy in Medicine (REALM) score <44, that is, unable to read simple health materials), 38.8% had positive Single Item Literacy Screener (SILS) scores (⩾2, require help to read medicines information) and 66.9% had inadequate skills for comprehension, appraisal and decision-making with regard to health information (Health Literacy Skills Instrument-Short Form (HLSI-SF) score <70%). The level of access to and utility of MIL were low, 32.4% and 34.6%, respectively. The main factors associated with poor utility of the MIL were low patient health literacy, lack of guidelines on the use of MIL and MIL written in non-native languages. Conclusion: Low rates of health literacy and utility of MIL were observed among hypertensive patients in Namibia. The integration of health literacy programmes, and MIL guidelines are needed to promote utility of medicine information and improve medication adherence.


  • Open Access

    Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future

    by Brian Godman, Debashis Basu, Yogan Pillay, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Bene D. Anand Paramadhas, Celda Tiroyakgosi, Patrick Mbah Okwen, Loveline Lum Niba, Justice Nonvignon, et al.

    Background: There has been an appreciable increase in the number of people in Africa with metabolic syndrome and Type 2 diabetes (T2DM) in recent years as a result of a number of factors. Factors include lifestyle changes, urbanisation, and the growing consumption of processed foods coupled with increasing levels of obesity. Currently there are 19 million adults in Africa with diabetes, mainly T2DM (95%), estimated to grow to 47 million people by 2045 unless controlled. This has a considerable impact on morbidity, mortality and costs in the region. There are a number of issues to address to reduce the impact of T2DM including improving detection rates and current access to services alongside addressing issues of adherence to prescribed medicines. There are also high rates of co-morbidities with infectious diseases such as HIV and tuberculosis in patients in Africa with T2DM that require attention. Objective: Document ongoing activities across Africa to improve the care of patients with T2DM especially around issues of identification, access, and adherence to changing lifestyles and prescribed medicines. In addition, discussing potential ways forward to improve the care of patients with T2DM based on ongoing activities and experiences including addressing key issues associated with co-morbidities with infectious diseases. Our Approach: Contextualise the findings from a wide range of publications including internet based publications of national approaches coupled with input from senior level government, academic and other professionals from across Africa to provide future guidance. Ongoing Activities: A number of African countries are actively instigating programmes to improve the care of patients with T2DM starting with improved diagnosis. This recognises the growing burden of non-communicable diseases across Africa, which has been neglected in the past. Planned activities include programmes to improve detection rates and address key issues with diet and lifestyle changes, alongside improving monitoring of care and activities to enhance adherence to prescribed medicines. In addition, addressing potential complexities involving diabetes patients with infectious disease co-morbidities. It is too early to fully assess the impact of such activities, Conclusion: There are a number of ongoing activities across Africa to improve the management of patients with diabetes including co-morbidities. However, more needs to be done considering the high and growing burden of T2DM in Africa. Ongoing research will help further benefit resource allocation and subsequent care.


  • Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future

    by Brian Godman, Debashis Basu, Yogan Pillay, Paulo H. R. F. Almeida, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Bene D Anand Paramadhas, Celda Tiroyakgosi, Okwen Patrick, Loveline Lum Niba, et al.

    Currently about 19 million people in Africa are known to be living with diabetes, mainly Type 2 diabetes (T2DM) (95%), estimated to grow to 47 million people by 2045. However, there are concerns wi...


  • Open Access

    Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

    by Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, et al.

    Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.


  • A robust tool for recording pharmacist's interventions in a low-resource setting

    by Timothy Rennie, Liisa Anguuo, Nicola Corkhill, Mwangana Mubita, Christian John Hunter


  • Monitoring of gentamicin serum concentrations in obstetrics and gynaecology patients in Namibia

    by Bonifasius S. Singu, Mwangana Mubita, Moses M. Thikukutu, Josef K. Mufenda, Shonag B. McKenzie, Roger K. Verbeeck

    Background Therapeutic drug monitoring is frequently used to optimize the gentamicin dose. Objective The study investigated whether a 240 mg once daily standard dose achieves the recommended target serum gentamicin concentrations. Setting The prospective, observational study took place in the 2 major public hospitals in Namibia. Method Twenty-nine female patients receiving a standard dose (240 mg gentamicin once daily) participated in the study. Two blood samples were withdrawn to estimate gentamicin pharmacokinetic parameters. Serum creatinine was used to calculate creatinine clearance with the Cockcroft–Gault formula (CLcr), and estimate glomerular filtration rate (eGFR) by the Modified Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. Main outcome measure The outcome measure was the proportion of patients receiving 240 mg gentamicin once daily having Cmax values above 15 mg/L. Results Total body weight (TBW) and body mass index were highly variable: 43–115 kg, and 17.3–41.3 kg/m2, respectively. The gentamicin dose normalized for TBW (adjusted body weight for obese patients) was relatively low, i.e. 4.2 ± 0.8 mg/kg (mean SD). Gentamicin Cmax was 14.4 ± 4.7 mg/L; only 9 patients (31%) had a Cmax > 15 g/mL. eGFR (MDRD-4) correlated well with CLcr, but eGFR (EPI-CKD) formula showed systematic deviations from CLcr. Conclusions (1) a standard 240 mg dose results in gentamicin Cmax values below 15 mg/L in the majority of the patients, (2) eGFR formulas to estimate kidney function will have to be evaluated for their usefulness in the Namibian patient population.


  • Open Access

    Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications

    by M. M. Nashilongo, B. Singu, F. Kalemeera, M. Mubita, E. Naikaku, A. Baker, A. Ferrario, B. Godman, L. Achieng, D. Kibuule

    Namibia has the highest burden and incidence of hypertension in sub-Sahara Africa. Though non-adherence to antihypertensive therapy is an important cardiovascular risk factor, little is known about potential ways to improve adherence in Namibia following universal access. The objective of this study is to validate the Hill-Bone compliance scale and determine the level and predictors of adherence to antihypertensive treatment in primary health care settings in sub-urban townships of Windhoek, Namibia.